DiaMedica Therapeutics develops DM199, an experimental protein therapy for preeclampsia, fetal growth restriction and acute ischemic stroke. It last closed at $8.38 on Nov 17, up 0.60% on the day. DMAC last reported earnings on Thu, Nov 12, 2026.
DMAC · as of the Nov 17 close · updated after every close
Moving sideways
The stock sits between its 20 and 50 day averages. It is 14% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 45). The nearest support is the Pivot at $8.31, and the nearest resistance the swing high (Jul 6) at $8.53.
Short trendNeutral
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 8.3%/day
Key levels
$10.9852 week high+31.0%
$9.2220 day average+10.0%
$8.71Pivot R1+3.9%
$8.53Swing high (Jul 6)+1.8%
$8.38Last close
$8.31Pivot−0.8%
$8.2750 day average−1.3%
$7.99Pivot S1−4.7%
$7.66Swing low (Oct 8)−8.6%
$7.59100 day average−9.4%
$7.18200 day average−14.3%
$5.2552 week low−37.4%
Indicators
RSI (14)
44.53
Middle of its range
Neutral
MACD
0.16
Below its signal line
Bearish
Stochastic
13.3
Near the bottom of its range
Oversold
ADX (14)
25.0
Trending down
Williams %R
-84.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-128.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−16.2%
Change over 10 sessions
Bearish
ATR (14)
$0.69
Typical daily range, 8.3% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
Uptrend
Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityNormal, 13.1%/day
Key levels
$10.9852 week high+31.0%
$9.2220 day average+10.0%
$8.71Pivot R1+3.9%
$8.53Swing high (Jul 6)+1.8%
$8.38Last close
$8.31Pivot−0.8%
$8.2750 day average−1.3%
$7.99Pivot S1−4.7%
$7.66Swing low (Oct 8)−8.6%
$7.59100 day average−9.4%
$7.18200 day average−14.3%
$5.2552 week low−37.4%
Indicators
RSI (14)
56.85
Middle of its range
Neutral
MACD
0.56
Above its signal line
Bullish
Stochastic
55.1
Middle of its range
Neutral
ADX (14)
25.9
Trending up
Williams %R
-54.6
Oversold below −80, overbought above −20
Neutral
CCI (20)
72.4
Oversold below −100, overbought above 100
Neutral
Rate of change
+29.5%
Change over 10 sessions
Bullish
ATR (14)
$1.10
Typical daily range, 13.1% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for DMAC
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how DMAC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow DMAC usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How DMAC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2012.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DMAC is in one of them and how their past DMAC trades turned out.
DiaMedica Therapeutics is a biopharmaceutical company based in Minneapolis, Minnesota. It is developing DM199, a recombinant form of the human tissue kallikrein-1 protein, as a possible treatment for preeclampsia, fetal growth restriction and acute ischemic stroke. The drug is still in clinical trials and is not yet approved for sale. The company is also working on DM300, a recombinant ulinastatin, as a possible treatment for severe acute pancreatitis.